Correction to: Bringing cell therapy to tumors: considerations for optimal CAR binder design [0.03%]
Correction to: 带着细胞疗法去找肿瘤：关于最佳CAR结合子设计的考虑因素
[This corrects the article DOI: 10.1093/abt/tbad019.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 Feb 14;7(2):131. DOI:10.1093/abt/tbae003 2024
Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA [0.03%]
采用加速质量谱和酶联免疫吸附法互补研究rhIL-7-hyFC的药代动力学行为
Anhye Kim,Min-Seok Oh,Gwan-Ho Lee et al.
Anhye Kim et al.
Antibody-based therapeutics (ABTs), including monoclonal/polyclonal antibodies and fragment crystallizable region (Fc)-fusion proteins, are increasingly used in disease treatment, driving the global market growth. Understanding the pharmaco...
Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential [0.03%]
一种具有抗过敏和抗癌潜力的新型人源化TSLP单克隆抗体HZ-1127的研究开发
Xiaolei Liu,Jianzhong Han,Qian Wang et al.
Xiaolei Liu et al.
Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family and has been widely recognized as a master regulator of type 2 inflammatory responses at barrier surfaces. Recent studies found dysregulation of the TSLP-TSLP recep...
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy [0.03%]
GB12-09，一种双特异性抗体，针对IL4Rα和IL31Rα用于治疗特应性皮炎
Feiyan Deng,Yuxin Qiu,Xiangling Zhang et al.
Feiyan Deng et al.
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by dysregulated immune responses. The key mediators of AD pathogenesis are T helper 2 (TH2) cells and TH2 cytokines. Targeting interleukin 4 (IL4), IL13 or IL31 h...
Multiple approaches to reduce reconstitution time of lyophilized drug products with high protein concentration [0.03%]
高蛋白浓度冻干药物产品的多种复溶时间缩短方法
Xiaozhang Zhang,Ningning Zhou,Chunsheng Yang et al.
Xiaozhang Zhang et al.
Background: Lyophilized drug products with high protein concentration often perform long reconstitution time, which is inconvenient for clinical use. The objective of this work is to achieve short reconstitution time with...
Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies [0.03%]
Fc区甘cosylation对Wnt拟似激动抗体活性的影响
Hui Chen,Sung-Jin Lee,Brian Ouyang et al.
Hui Chen et al.
Monoclonal antibodies have been explored in a broad range of applications including receptor agonism. Given the importance of receptor conformation in signaling, the agonistic activity of antibodies that engage these receptors are influence...
ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks [0.03%]
针对SARS-CoV-2和MERS-CoV变异体的ACE2-Fc和DPP4-Fc诱饵受体：针对当前及未来冠状病毒疫情的一种快速治疗选择
Mohamed A Alfaleh,Reem M Alsulaiman,Sarah A Almahboub et al.
Mohamed A Alfaleh et al.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the Middle East respiratory syndrome coronavirus (MERS-CoV) are highly pathogenic human coronaviruses (CoVs). Anti-CoVs mAbs and vaccines may be effective, but the emergen...
Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs [0.03%]
从DNA到IND，进一步加快生物制剂的开发：从COVID-19项目到非COVID-19项目的过程
Kee Wee Tan,Pengfei Ji,Hang Zhou et al.
Kee Wee Tan et al.
The Coronavirus Disease (COVID-19) pandemic has spurred adoption of revolutionary initiatives by regulatory agencies and pharmaceutical industry worldwide to deliver therapeutic COVID-19 antibodies to patients at unprecedented speed. Among ...
Challenges and solutions for the downstream purification of therapeutic proteins [0.03%]
治疗蛋白下游纯化的挑战与解决方案
Shuo Tang,Jiaoli Tao,Ying Li
Shuo Tang
The innovation in recombinant protein technology has brought forth a host of challenges related to the purification of these therapeutic proteins. This article delves into the intricate landscape of developing purification processes for art...
Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML [0.03%]
Fcγ受体促进抗体诱导的LILRB4内化和单核细胞AML的免疫调节
Joshua W Morse,Xun Gui,Mi Deng et al.
Joshua W Morse et al.
The immune checkpoint leukocyte immunoglobulin-like receptor B4 (LILRB4) is found specifically on the cell surface of acute monocytic leukemia (monocytic AML), an aggressive and common subtype of AML. We have developed a humanized monoclona...